Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4892
Source ID: NCT06192108
Associated Drug: Orforglipron
Title: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Acronym: ACHIEVE-2
Status: ACTIVE_NOT_RECRUITING
Study Results: NO
Results:
Conditions: Type 2 Diabetes
Interventions: DRUG: Orforglipron|DRUG: Dapagliflozin
Outcome Measures: Primary: Change from Baseline in Hemoglobin A1c: (HbA1c), Baseline, Week 40 | Secondary: Change from Baseline in HbA1c, Baseline, Week 40|Percentage of Participants Who Achieved HbA1c <7.0% (53 millimole/mole(mmol/mol)), Week 40|Percentage of Participants Who Achieved HbA1c ≤6.5% (48 mmol/mol), Week 40|Percentage Change from Baseline in Body Weight, Baseline, Week 40|Change from Baseline in Body Weight, Baseline, Week 40|Percentage Change from Baseline in Non-High-Density Lipoprotein (non-HDL)-Cholesterol, Baseline, Week 40|Percentage Change from Baseline in Triglycerides, Baseline, Week 40|Change from Baseline in Systolic Blood Pressure (SBP), Baseline, Week 40|Change from Baseline in Fasting Serum Glucose, Baseline, Week 40|Percentage of Participants Who Achieved Weight Loss of ≥5% from Baseline, Baseline to Week 40|Percentage of Participants Who Achieved Weight Loss of ≥10% from baseline, Baseline to Week 40|Percentage of Participants Who Achieved Weight Loss of ≥15% from baseline, Baseline to Week 40|Change from Baseline in Diastolic Blood Pressure (DBP), Baseline, Week 40|Percentage Change from Baseline in Total Cholesterol, Baseline, Week 40|Change from Baseline in Short Form 36 Version 2 (SF-36-v2) Acute Form Domain Summary Scores, Baseline, Week 40|Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Change (DTSQc) Scores, Baseline, Week 40
Sponsor/Collaborators: Sponsor: Eli Lilly and Company
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 888
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2024-01-10
Completion Date: 2025-09
Results First Posted:
Last Update Posted: 2025-02-28
Locations: Alliance Research Institute - Canoga Park, Canoga Park, California, 91304, United States|Ark Clinical Research, Long Beach, California, 90815, United States|Collaborative Neuroscience Research, LLC, Los Alamitos, California, 90720, United States|Wolverine Clinical Trials, Tustin, California, 92780, United States|CMR of Greater New Haven, LLC, Hamden, Connecticut, 06517, United States|Institute of Endocrinology Diabetes, Health & Hormone, Stockbridge, Georgia, 30281, United States|Elite Clinical Trials, Rexburg, Idaho, 83440, United States|Accellacare - DuPage, Lombard, Illinois, 60148, United States|Tandem Clinical Research, Marrero, Louisiana, 70072, United States|St. Vincent Healthcare, Billings, Montana, 59101, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, 87102, United States|Accellacare - Winston-Salem, Winston-Salem, North Carolina, 27103, United States|Alliance for Multispecialty Research, LLC, Norman, Oklahoma, 73069, United States|Essential Medical Research, Tulsa, Oklahoma, 74137, United States|Accellacare - Mt Pleasant, Mount Pleasant, South Carolina, 29464, United States|Accellacare, US Inc., d/b/a Accellacare of Knoxville, Jefferson City, Tennessee, 37760, United States|Velocity Clinical Research, Dallas, Dallas, Texas, 75230, United States|Juno Research, Houston, Texas, 77040, United States|Consano Clinical Research, LLC, Shavano Park, Texas, 78231, United States|The Second People's Hospital of Hefei, Hefei, Anhui, 230011, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China|The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan, 473007, China|The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450014, China|Nanjing First Hospital, Nanjing, Jiangsu, 210006, China|The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210011, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China|Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, 212000, China|Jinan Central Hospital, Jinan, Shandong, 250013, China|Shanghai Sixth People's Hospital, Shanghai, Shanghai, China|First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650032, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China|CRS Clinical Research Services Mannheim, Mannheim, Baden-Württemberg, 68167, Germany|Diabetologische Schwerpunktpraxis Dr. Staudenmeyer & Dr. Schiwietz, Lingen, Niedersachsen, 49808, Germany|Diabetes- und Stoffwechselpraxis Bochum, Bochum, Nordrhein-Westfalen, 44869, Germany|InnoDiab Forschung Gmbh, Essen, Nordrhein-Westfalen, 45136, Germany|Medizentrum Essen Borbeck, Essen, Nordrhein-Westfalen, 45355, Germany|Zentrum fur klinische Forschung - Köln, Köln, Nordrhein-Westfalen, 51069, Germany|Institut für Diabetesforschung GmbH Münster, Münster, Nordrhein-Westfalen, 48145, Germany|Praxis Dr. Veronika Wenzl-Bauer, Rehlingen, Saarland, 66780, Germany|Zentrum für klinische Studien, Saint Ingbert, Saarland, 66386, Germany|RED-Institut GmbH, Oldenburg, Schleswig-Holstein, 23758, Germany|Diabetes Zentrum Wilhelmsburg, Hamburg, 21109, Germany|Cryptex Investigación Clínica S.A. de C.V., Cuauhtémoc, Ciudad De México, Distrito Federal, 06100, Mexico|ProcliniQ Investigación Clínica SA de CV, Mexico City, Distrito Federal, 14050, Mexico|Grupo Ollin Care, Pachuca, Hidalgo, 42000, Mexico|Instituto Jalisciense de Investigacion en Diabetes y Obesidad, Guadalajara, Jalisco, 44600, Mexico|Instituto de Diabetes, Obesidad y Nutricion, Cuernavaca, Morelos, 62250, Mexico|Invecordis S.C., Hacienda De Las Palmas, México, 52763, Mexico|Cardiolink Clin Trials, Monterrey, Nuevo León, 64060, Mexico|Clínica García Flores SC, Monterrey, Nuevo León, 64610, Mexico|Servicios Integrales Nova de Monterrey S.A. de C.V., San Nicolas de los Garza, Nuevo León, 66450, Mexico|Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C., Culiacan, Sinaloa, 80230, Mexico|Consultorio de Medicina Especilizada del Sector Privado, Xalapa, Veracruz, 91193, Mexico|Hospital Angeles Xalapa, Xalapa, Veracruz, 91193, Mexico|Fundación Cardiovascular de Aguascalientes A.C., Aguascalientes, 20230, Mexico|Lahoja. Asociacion Para La Investigacion Y La Farmacovigilancia, Durango, 34000, Mexico|PanAmerican Clinical Research - Querétaro - Avenida Antea, Querétaro, 76100, Mexico|Centrum Badań Klinicznych Piotr Napora lekarze sp.p., Wroclaw, Dolnośląskie, 50-162, Poland|NZOZ Centrum Medyczne KERmed, Bydgoszcz, Kujawsko-pomorskie, 85-231, Poland|Clinical Best Solutions, Lublin, Lubelskie, 20-011, Poland|CenterMed Lublin NZOZ, Lublin, Lubelskie, 20-044, Poland|Ekamed, Lublin, Lubelskie, 20-718, Poland|Centrum Medyczne "Diabetika", Radom, Mazowieckie, 26-600, Poland|Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET, Krakow, Małopolskie, 31-261, Poland|Zdrowie Osteo-Medic, Bialystok, Podlaskie, 15-351, Poland|Specderm Poznanska, Bialystok, Podlaskie, 15-375, Poland|Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz, Łódzkie, 90-338, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 SUM, Zabrze, Śląskie, 41-800, Poland|Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung, 81362, Taiwan|Fu Jen Catholic University Hospital, New Taipei, 24352, Taiwan|Taichung Veterans General Hospital, Taichung, 407, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan
URL: https://clinicaltrials.gov/show/NCT06192108

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D445 Dapagliflozin small molecule DB06292 Details